Nicholas Wrigley is a writer and editor for CancerNetwork and the journal ONCOLOGY.
He is also a writer of fiction; his work has appeared in a local anthology, the Best Short Stories of Philadelphia, and elsewhere. He holds an MFA in Creative Writing from Temple University and spends most of his spare time reading books, writing books, playing video games, or sleeping. He has inexplicably strong opinions on Russian history, Star Wars, and pasta. He lives in Greater Philadelphia with his family and, more importantly, his two dogs.
The first-in-class Heat Shock Factor 1 pathway inhibitor NXP800, the subject of an ongoing phase 1 dose-escalation study, has been granted a Fast Track designation for the treatment of platinum-resistant ovarian cancer by the FDA.
An expert from NYU Langone in New York City recently discussed the strengths and limitations of the oral tyrosine kinase inhibitor mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion+ metastatic non-small cell lung cancer.
The use of hypomethylating drugs such as azacitidine and decitabine improved outcomes for patients of advanced age with acute myeloid leukemia, according to findings from a recent retrospective study of real-world data.
Findings from a recent 30-year analysis of more than 1,000 gynecologic cancer trials strongly suggest that reporting race and ethnicity must be a required part of clinical research to improve diversity, according to a group of researchers.
Erica C. Nakajima, MD, discussed a pooled analysis analyzing immune checkpoint inhibitors with or without chemotherapy in the frontline treatment of patients with KRAS-mutated non-small cell lung cancer and PD-L1 expression.
Factors such as chemotherapy treatment and a cancer diagnosis within the past 5 years were associated with a greater risk of frailty-related bone fractures among older cancer survivors, according to findings from a recent cohort study.